Jonakayem Pharma Formulation (OPC) Pvt. Ltd.
VINCRISTINE

VINCRISTINE

Send Inquiry
Product: VINCRISTINE
Formulary: Generic Formulary
Category: Neoplastics
Sub Group: ANTI NEOPLASTIC AGENTS
International Brand Name: Oncovin
Dosages: 1 mg/ml
Unit of Packing: Inj-1ml
In treatment of: Treatment of acute Leukemia

Contraiindication: 

  • Hypersensitivity to the drug
  • Demyelinating form of Charcot-Marie-Tooth syndrome 
  • Recent radiation therapy

Special Precaution: 

  •  Infection
  • Neuromuscular disease
  • Leucopenia 
  • Pulmonary disorder 
  • Leukemia 
  • Radiation therapy 
  • Extravasations 
  • Treatment with neurotoxic drug
  • Recent vaccination

Adverse Effects: 

  • Nausea 
  • Vomiting
  • Lowered resistance to infection 
  • Bruising or unusual bleeding 
  • Anemia 
  • Weakness
  • Sore in mouth 
  • Taste changes 
  • Diarrhea 
  • Loss of appetite 
  • Visual changes 
  • Black, tarry stools 
  • Blood in urine or in stool 
  • Cough or hoarseness 
  • Fever 
  • Chills 
  • Lower back or side pain 
  • Painful or difficult urination 
  • Pinpoint red spot on skin
  • Slurred speech 
  • Swelling on leg or lower leg 
  • Shortness of breath 
  • Pulmonary fibrosis 
  • Intestinal necrosis 
  • Hypotension 
  • Stomatitis 
  • Disorientation 
  • Lethargy 
  • Ataxia 
  • Thrombocytopenia 
  • Leucopenia 
  • Bone marrow suppression 
  • Hypertension 
  • Acute Bronchospasm 
  • Reversible alopecia 
  • Phlebitis 
  • Cellulitis at the site of injection

 

Interaction: Digoxin: Decreased plasma digoxin levels and renal excretion. L-asparaginase: Hepatic clearance of vincristine is reduced if L-asparaginase is administered first. Thus to minimise toxicity, vincristine should be given 12 to 24 hours before administering L- asparaginase. Mitomycin-C: Acute pulmonary reaction may occur. Phenytoin: Reduced phenytoin plasma levels.

Servings: Intravenous- Adult- 10 - 30 mcg/kg or 0.4 - 1.4mg/metre square /weekly Children- 1.5 - 2 mg/metre square/weekly